Trial reportAIDS and behavior2018
Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants.
Trial report in AIDS and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.Journal of the International AIDS Society · 2023Pooled it
- What are the views of those participating in a trial investigating acute post-traumatic benign paroxysmal positional vertigo? A qualitative study.Brain injury · 2025Trial
- Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.AIDS and behavior · 2020Trial
- What Do People with HIV Want to Know About Long-Acting Injectable Cabotegravir/Rilpivirine?AIDS and behavior · 2026Article
- HIV Treatment and Program Preferences Among Ryan White Clients in New York City in the Era of Long-Acting Injectable ART: A Discrete Choice Experiment.medRxiv : the preprint server for health sciences · 2026Article
- Utilisation of HIV pre-exposure prophylaxis and preferences of alternative long-acting modalities among men who have sex with men in Hong kong: a cross-sectional study.BMC public health · 2025Article
- Behind Prep Decisions: Understanding User Patterns and Discontinuation Factors in Real-World.AIDS and behavior · 2024Article
- Interest in I-PrEP and Willingness to Participate in Clinical Trials Among Men and Transfeminine Persons Who have Sex with Men in Sub-Saharan Africa: Quantitative and Qualitative Findings from HPTN 075.AIDS and behavior · 2024Article
- Optimizing the pipeline of multipurpose prevention technologies: opportunities across women's reproductive lifespans.Frontiers in reproductive health · 2023Review
- Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.Drugs · 2022Review
- Practices of patient engagement in drug development: a systematic scoping review.Research involvement and engagement · 2022Article
- The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States.AIDS research and therapy · 2022Article
- Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).AIDS and behavior · 2021Article
- A Scoping Review Investigating Relationships between Depression, Anxiety, and the PrEP Care Continuum in the United States.International journal of environmental research and public health · 2021Article
- Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.Clinical trials (London, England) · 2021Article
- Article
- The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment.Current opinion in HIV and AIDS · 2020Review
- Long-acting injectable cabotegravir for the prevention of HIV infection.Current opinion in HIV and AIDS · 2020Review
- Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis.Current opinion in HIV and AIDS · 2020Review
- Mosaic effectiveness: measuring the impact of novel PrEP methods.The lancet. HIV · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
This study aimed to identify patients' physical and psychosocial experiences of an investigational long-acting injectable PrEP product to aid in the development of patient and provider education materials. Twenty-eight participants of a Phase 2 safety, tolerability, and acceptability study of long-acting integrase inhibitor cabotegravir (CAB-LA) were interviewed on their physical and psychosocial experiences of the injections. Five themes emerged through a framework analysis on these interview transcripts: (1) injection-related pain is highly variable across individuals; (2) pain is more impactful after the injections than during; (3) patient anxiety is critical, but does not determine the experience of injections and decreases over time; (4) intimacy and awkwardness of gluteal injections impacts patients' experiences; (5) patient education and care strategies can mitigate the above factors. These findings can inform further sociobehavioral research within Phase 3 efficacy trials of CAB-LA, as well as patient education and provider guidance for future injectable PrEP products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.